Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to quantify the total blood serum levels of bupivacaine in
OrthoPAT® collected blood 2 hours and 5 hours postoperatively.
Hypothesis: Filtered blood from the OrthoPAT® autotransfusion system contains low or
undetectable levels of bupivacaine hydrochloride (HCL). Reinfusion of collected blood from
the OrthoPAT® device when used in conjunction with periarticular bupivicaine injections will
not pose a bupivocaine toxicity risk to patients undergoing a total joint arthroplasty.